Fate Therapeutics Files 8-K: Director Changes & Bylaw Amendments
Ticker: FATE · Form: 8-K · Filed: May 30, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | May 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, board-changes, bylaws
TL;DR
Fate Therapeutics 8-K: Board shakeup and bylaw changes filed May 29, 2025.
AI Summary
On May 29, 2025, Fate Therapeutics, Inc. filed an 8-K report detailing several key events. These include the departure of directors, the election of new directors, and updates to compensatory arrangements for certain officers. The company also announced amendments to its articles of incorporation or bylaws and a change in its fiscal year.
Why It Matters
Changes in board composition and corporate governance can signal shifts in strategic direction or operational focus for the company.
Risk Assessment
Risk Level: medium — Changes in board composition and potential bylaw amendments can indicate internal restructuring or strategic shifts that may impact future performance.
Key Numbers
- 12-31 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- May 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36076 (company_id) — SEC File Number
- 65-1311552 (ein) — IRS Employer Identification No.
- 12278 Scripps Summit Dr. (address) — Business address
- San Diego, CA 92131 (address) — Business address
FAQ
Who are the departing directors and newly elected directors?
The filing indicates the departure of directors and the election of new directors, but specific names are not provided in this excerpt.
What specific amendments were made to the articles of incorporation or bylaws?
The filing states that amendments to articles of incorporation or bylaws were submitted, but the details of these amendments are not included in this summary.
What is the nature of the changes in compensatory arrangements for certain officers?
The report mentions changes to compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed in this excerpt.
What is the reason for the change in fiscal year?
The filing notes a change in fiscal year, but the rationale behind this change is not provided in this excerpt.
What matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific proposals are not detailed in this excerpt.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding FATE THERAPEUTICS INC (FATE).